Sy Mukherjee
Fortune
New York, NY, United States
Contact Sy
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Sy:
Intellia stock: What the CRISPR biotech's success means for the gene-editing industry
A groundbreaking CRISPR treatment from Intellia Therapeutics sent the company's stock soaring and could lift the entire gene-editing industry's prospects by transforming DNA inside of a human body. → Read More
The COVID Delta variant is infecting some fully vaccinated adults in Israel. Should you be worried?
A number of Israeli adults who were fully vaccinated with Pfizer's COVID vaccine were infected by the Delta variant. But the issue comes with plenty of nuance. → Read More
Articles by Sy Mukherjee
© 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell My Personal Information | Ad Choices FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services… → Read More
The secret to checking items off the corporate to-do list? Decluttering, says Poo~Pourri CEO
"I want more clarity and communication," says Poo~Pourri and Supernatural CEO and founder Suzy Batiz at Fortune's MPW Next Gen conference. And she means in every aspect of business from emails to office space. → Read More
The delta between the Delta variants
There's another new COVID variant that has the potential to wreak havoc. The key word there is "potential." → Read More
A mutation of a mutation: What you need to know about the COVID Delta Plus variant
There's yet another COVID mutation that's spreading in certain countries. But just how concerned should the world be about the Delta Plus variant? → Read More
The U.S. won’t make the President’s July 4 vaccination target. Here’s what that means
The White House admits we won't hit 70% of adults with at least one COVID shot by the 4th of July - but just barely. → Read More
Pressure mounts on Biden to nominate permanent FDA head as dissatisfaction with agency grows
Sen. Joe Manchin is taking a tough stance against acting FDA chief Janet Woodcock following Biogen's controversial Alzheimer's drug approval. But we still don't know who President Biden will appoint to the permanent position. → Read More
3 Black diversity chiefs on how they’ll fight racial inequality in medicine
On this Juneteenth, the chief diversity, equity, and inclusion officers of Pfizer, UnitedHealth Group, and Kaiser Permanente tell Fortune how they plan to tangibly address health inequality in Black communities. → Read More
Three Black health care diversity officers. One united goal
Black chief diversity officers discuss health inequality in medicine and what they want to do about it. → Read More
The decade-long battle against Obamacare reaches a likely end with new Supreme Court decision
On Thursday, the Supreme Court hammered what is likely the final nail in the coffin for Obamacare foes. → Read More
What you should know about the Delta variant and what it means for re-opening
The COVID delta variant strain is a growing concern as it could lead to more serious illness and coronavirus infections, according to the CDC. → Read More
What we know about COVID vaccines, heart inflammation, and its implications for drug makers
The CDC is convening an emergency meeting after rare cases of heart swelling in those who received mRNA-based COVID vaccines. Here's what we know and what it means for the industry. → Read More
What comes next after the Biogen Alzheimer’s drug approval
Biogen's Alzheimer's drug approval could pave the way for major changes across the industry. → Read More
Biogen won its controversial Alzheimer’s drug approval. Which drugmakers will see the next big win?
With the precedent set, the FDA's decision to approve Biogen's Alzheimer's drug could cause ripple effects across the industry in multiple diseases. → Read More
FDA approves historic Biogen Alzheimer's drug aducanumab—marketed as Aduhelm—the first treatment of its kind.
The FDA on Monday granted a historic approval to Biogen's closely-watched, and highly controversial, Alzheimer's drug aducanumab, the first treatment of its kind. → Read More
The health care companies leading 2021’s Fortune 500 list
Health care companies across the gamut of the industry scored big in the 2021 Fortune 500 list. → Read More
Abortion, Obamacare, and drug approvals: American health care faces a pivotal moment
From to the future of Obamacare to abortion rights to drug approvals, we're at a pivotal moment in American health care policy. → Read More
The U.S. military had a COVID vaccine skepticism problem. But now it’s seeing a massive jump in shots
COVID vaccinations among the U.S. military have jumped 55% in the past month, a remarkable turnaround given many servicemembers' hesitancy about the vaccine. → Read More
Congress loves a Big Pharma villain. But will that lead to any real policy changes on drug prices?
AbbVie has never been shy about guarding its patents and hiking drug prices. Congress tore into the company this week. But will it lead to any real policy change? → Read More